Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)

  • Protocol
  • Intervention

Authors

  • Nicole Bergner,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Sabine Kluge,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Ina Monsef,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Gerald Illerhaus,

    1. University Hospital of Freiburg, Department I of Internal Medicine, Freiburg, Germany
    Search for more papers by this author
  • Andreas Engert,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Nicole Skoetz

    Corresponding author
    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    • Nicole Skoetz, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. nicole.skoetz@uk-koeln.de.

    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this Cochrane review is to evaluate the role of additional chemotherapy to HD-MTX in the treatment of immunocompetent PCNSL patients with respect to overall survival (OS), progression-free survival (PFS), response rate, adverse events (AE), treatment-related mortality (TRM) and quality of life (QoL).